NEW YORK (GenomeWeb) – Rosetta Genomics today released preliminary fourth quarter financial results for its RosettaGX Reveal thyroid nodule assay, reporting a 38 percent increase in test sales over the third quarter.

For the three-month period ended Dec. 31, Reveal generated preliminary revenues of $390,000 versus $282,000 in the third quarter. During the fourth quarter, Rosetta received 423 orders for the test compared with 305 units received in the previous quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.